Top member reports
No meetings
Consensus community valuation
The consensus valuation is for members only and has been removed from this chart. Click for membership options.
Contributing Members
Content is delayed by one month. Upgrade your membership to unlock all content. Click for membership options.
Valuation of $0.060
stale
Added 2 years ago

Price - Explodes

like E. Musk Space X - Accelerated Dismantling ...lol

Read More
#Investor Presentation - Quarte
stale
Added 2 years ago

FDA on PXS - 5505 myelofibrosis ongoing study

74b2cb645d3abb1720c82f9c1ad7ea04da4537.png

39de8cb467563764ce1ab240298898a219d809.png9860ca082483d8f35a8ecb6e00f8007fe4f09a.png

The science in the charts below

1b77d0070ed4b619a944b93bc60fd4908085e0.png


Read More
#FDA Review PXS Accelerates Pla
stale
Added 2 years ago

Phase 2 clinical trial of PXS‐5505 in myelofibrosis (MF). Following helpful feedback from the U.S. Food and Drug Administration (FDA), the trial will be widened to include myelofibrosis patients already receiving a JAK inhibitor as standard of care in combination with PXS‐5505

73de27214090c1a3d13c1980d33a27e857c2c3.png

6b6a7298cec7f1021d9996f1aa657ab57560d3.png

Read More
#Chiesi $7m milestone payment
stale
Added 4 years ago

29-Dec-2020:  Pharmaxis Receives US$7m milestone from Chiesi

Also:  Pharmaxis email communication to those on their email list about today's announcement

Pharmaxis Receives US$7m Milestone

Pharmaceutical research company Pharmaxis Ltd (ASX: PXS) has today received a US$7 million (~A$9.2 million) milestone payment from its US licensee Chiesi Farmaceutici S.p.A. (Chiesi) following the recent approval by the US Food Drug Administration (FDA) of Bronchitol®(mannitol) for the treatment of cystic fibrosis.

A further US$3 million is payable by Chiesi on shipment by Pharmaxis of commercial launch stock, scheduled for the first quarter of 2021.

Pharmaxis reported cash funds of A$10 million at 30 September 2020 to which it has since added a R&D tax incentive of $5 million in October and this milestone of A$9 million.

On 2 November 2020 it was announced that the FDA had approved Bronchitol, the drug Pharmaxis developed, for the treatment of adult cystic fibrosis patients in the United States.

--- ends ---

Read More